Clinical trial • Phase I • Oncology
GEN3018 for Relapsed or refractory acute myeloid leukemia | High-risk myelodysplastic syndrome
Phase I trial of GEN3018 for Relapsed or refractory acute myeloid leukemia | High-risk myelodysplastic syndrome. 40 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Relapsed or refractory acute myeloid leukemia | High-risk myelodysplastic syndrome
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 12-11-2025
- First CTIS Authorization Date
- 16-01-2026
Trial design
Phase I trial across 6 sites in Denmark, Spain.
- Target Sample Size
- 40
Eligibility
Recruits 40 Vulnerable population selected; no details on consent or assent handling provided in the record..
- Vulnerable Population
- Vulnerable population selected; no details on consent or assent handling provided in the record.
Recruitment
- Planned Sample Size
- 40
- Recruitment Window Months
- 20
Geography
- Total Number Of Sites
- 6
- Total Number Of Participants
- 40
Denmark
- Earliest CTIS Part Ii Submission Date
- 19-12-2025
- Latest Decision Or Authorization Date
- 16-01-2026
- Processing Time Days
- 28
- Number Of Sites
- 2
- Number Of Participants
- 16
Sites
- Site Name
- Rigshospitalet
- Department Name
- Department of Haemotology
- Principal Investigator Name
- Claudia Schöllkopf
- Principal Investigator Email
- claudia.schoellkopf.01@regionh.dk
- Contact Person Name
- Claudia Schöllkopf
- Contact Person Email
- claudia.schoellkopf.01@regionh.dk
- Site Name
- Region Midtjylland
- Department Name
- Department of Hematology
- Principal Investigator Name
- Hans Beier Ommen
- Principal Investigator Email
- Hans.beier.ommen@rm.dk
- Contact Person Name
- Hans Beier Ommen
- Contact Person Email
- Hans.beier.ommen@rm.dk
Spain
- Earliest CTIS Part Ii Submission Date
- 17-02-2026
- Latest Decision Or Authorization Date
- 11-03-2026
- Processing Time Days
- 22
- Number Of Sites
- 4
- Number Of Participants
- 24
Sites
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Haematology
- Principal Investigator Name
- Jordi Esteve Reyner
- Principal Investigator Email
- jesteve@clinic.cat
- Contact Person Name
- Jordi Esteve Reyner
- Contact Person Email
- jesteve@clinic.cat
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Haematology
- Principal Investigator Name
- Olga Salamero Garcia
- Principal Investigator Email
- osalamero@vhio.net
- Contact Person Name
- Olga Salamero Garcia
- Contact Person Email
- osalamero@vhio.net
- Site Name
- Hospital Universitario 12 De Octubre
- Department Name
- Haematology
- Principal Investigator Name
- Pilar Martinez Sanchez
- Principal Investigator Email
- mariapilar.martinez.sanchez@salud.madrid.org
- Contact Person Name
- Pilar Martinez Sanchez
- Contact Person Email
- mariapilar.martinez.sanchez@salud.madrid.org
- Site Name
- Hospital Universitario Y Politecnico La Fe
- Department Name
- Haematology
- Principal Investigator Name
- Pau Montesinos Fernandez
- Principal Investigator Email
- montesinos_pau@gva.es
- Contact Person Name
- Pau Montesinos Fernandez
- Contact Person Email
- montesinos_pau@gva.es
Sponsor
Primary sponsor
- Full Name
- Genmab A/S
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- Denmark
Investigational products
- Investigational Product Name
- GEN3018
- First In Human
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)